CLOs on the Move

Sentien Biotechnologies Inc

www.sentienbiotech.com

 
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

Priovant Therapeutics

Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oncocyte

Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.